drugset
drugset / Trial / NCT02867592

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

NCT02867592 ↗

Phase 2 Active not recruiting 109 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth and tumor blood vessel growth.

Timeline

Start
2017-05-18
Primary completion
2021-06-30
Completion
2026-06-27

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cabozantinib Small molecule — Oral

Indications

Ewing sarcoma adrenal cortex carcinoma alveolar soft part sarcoma central nervous system cancer clear cell sarcoma hepatoblastoma kidney Wilms tumor medullary thyroid gland carcinoma osteosarcoma rhabdomyosarcoma